Bertrand Delsuc/X
Dec 18, 2024, 12:51
Bertrand Delsuc: 2 IO agents discontinued at once by $MRK
Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X:
“Wow, 2 IO agents discontinued at once by $MRK.
RIP anti TIGIT vibostolimab (2 NSCLC studies of pembro+visbosto declared futile+safety consistent with that observed for vibosto and pembro in previously reported studies (ie not good).
RIP anti LAG3 favezelimab (only 1 ph3 in cHL for pembro+fave) room made for the development of other candidates in $MRK’s comprehensive and diversified oncology pipeline.
Let me guess, like LM-299?
Merck $MRK Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab.”
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 18, 2024, 15:11
Dec 18, 2024, 15:08
Dec 18, 2024, 14:24
Dec 18, 2024, 14:21
Dec 18, 2024, 13:37
Dec 18, 2024, 13:34
Dec 18, 2024, 13:25